Platelets and endothelial dysfunction in gestational diabetes mellitus

Paola Valero1,2, Marcelo Cornejo1,2,3,4, Gonzalo Fuentes1,2,3

  • 1Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, Department of Obstetrics, Faculty of Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Insights

Gestational diabetes mellitus (GDM) is linked to increased obesity and vascular dysfunction. This review explores how altered platelets contribute to fetoplacental vascular issues in GDM, impacting fetal development.

Area of Science:

  • Obstetrics and Gynecology
  • Vascular Biology
  • Endocrinology

Background:

  • Gestational diabetes mellitus (GDM) prevalence is rising, coinciding with increased maternal obesity.
  • GDM causes vascular dysfunction in the fetoplacental unit, affecting nutrient transfer and pregnancy outcomes.
  • Endothelial dysfunction in GDM is recognized, but the role of other cells, like platelets, is less understood.

Purpose of the Study:

  • To review current findings on platelet alterations in GDM.
  • To investigate the link between platelet characteristics and GDM-associated endothelial dysfunction.
  • To propose a connection between platelet function, placental development, and fetoplacental vascular dysfunction in GDM.

Main Methods:

  • Literature review of studies investigating GDM, endothelial dysfunction, and platelet parameters.
  • Synthesis of evidence on platelet volume, mass, reactivity, and function in GDM.
  • Analysis of proposed mechanisms linking platelets to fetoplacental vascular pathology.

Main Results:

  • Several studies suggest a relationship between platelet volume/mass and GDM.
  • Platelet roles and signaling pathways in GDM-induced endothelial dysfunction remain unclear.
  • Altered platelet quantity, size, and function may impact placental development and fetoplacental vasculature.

Conclusions:

  • Platelets are implicated in GDM-associated endothelial dysfunction.
  • Further research is needed to elucidate specific platelet mechanisms in GDM.
  • Understanding platelet involvement could offer new insights into managing GDM complications.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
582
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
19
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K